- Home
- SHOO vs ACAD Comparison
SHOO vs ACAD Comparison
Compare SHOO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOO
- ACAD
- Stock Information
- Founded
- SHOO 1990
- ACAD 1993
- Country
- SHOO United States
- ACAD United States
- Employees
- SHOO N/A
- ACAD N/A
- Industry
- SHOO Shoe Manufacturing
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SHOO Consumer Discretionary
- ACAD Health Care
- Exchange
- SHOO Nasdaq
- ACAD Nasdaq
- Market Cap
- SHOO 2.8B
- ACAD 2.8B
- IPO Year
- SHOO 1993
- ACAD 2004
- Fundamental
- Price
- SHOO $19.90
- ACAD $14.73
- Analyst Decision
- SHOO Hold
- ACAD Buy
- Analyst Count
- SHOO 6
- ACAD 16
- Target Price
- SHOO $37.20
- ACAD $23.93
- AVG Volume (30 Days)
- SHOO 2.4M
- ACAD 1.8M
- Earning Date
- SHOO 04-30-2025
- ACAD 05-07-2025
- Dividend Yield
- SHOO 4.30%
- ACAD N/A
- EPS Growth
- SHOO 2.17
- ACAD N/A
- EPS
- SHOO 2.35
- ACAD 1.36
- Revenue
- SHOO $2,282,927,000.00
- ACAD $957,797,000.00
- Revenue This Year
- SHOO $19.85
- ACAD $13.07
- Revenue Next Year
- SHOO $8.48
- ACAD $9.88
- P/E Ratio
- SHOO $8.47
- ACAD $10.83
- Revenue Growth
- SHOO 15.21
- ACAD 31.85
- 52 Week Low
- SHOO $19.05
- ACAD $13.40
- 52 Week High
- SHOO $50.01
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- SHOO 30.46
- ACAD 38.07
- Support Level
- SHOO $19.41
- ACAD $14.34
- Resistance Level
- SHOO $21.61
- ACAD $15.18
- Average True Range (ATR)
- SHOO 1.66
- ACAD 0.80
- MACD
- SHOO -0.13
- ACAD -0.02
- Stochastic Oscillator
- SHOO 9.04
- ACAD 38.22
About SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its own stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.